This report provides exclusive insights into the COVID-19 impact on the Venous Thromboembolism Therapeutics Market. The detailed analysis provides information about the impact of the outbreak on the demand and supply conditions, trends and forecasts of the Venous Thromboembolism Therapeutics Market. Moreover, the impact analysis covers the study of the COVID-19 on the supply chain of Venous Thromboembolism Therapeutics Market. The sectoral impact shall provide insights into both short term and long term effects of the pandemic on the related and support industries.
A recent report published by Infinium Global Research on venous thromboembolism therapeutics market provides an in-depth analysis of segments and sub-segments in global as well as regional venous thromboembolism therapeutics market. The study also highlights the impact of drivers, restraints and macro indicators on the global and regional venous thromboembolism therapeutics market over the short term as well as long-term. The report is a comprehensive presentation of trends, forecast and dollar values of global venous thromboembolism therapeutics market. According to the report the global venous thromboembolism therapeutics market is projected to grow at a CAGR of 3.7 % over the forecast period of 2018-2024.
Venous thromboembolism (VTE) is a condition in which a blood clot forms most often in the deep veins of the leg, groin or arm and travels in the circulation, lodging in the lungs. VTE is a life-threatening medical condition that requires immediate medical treatment. This treatment primarily focuses on breaking the clots and countering further formation of clots. There are two types of VTE, deep vein thrombosis (DVT) and pulmonary embolism (PE). The venous thromboembolism therapeutics market was worth XX million in 2017 and is anticipated to reach XX million by 2024.
Key factors responsible for the growth of this market include the development of anticoagulants that are used to prevent the formation of new blood clots and to treat existing clots by preventing them from growing larger in size. It also reduces the risk of embolization of blood clots to other vital organs such as the lungs and brain. Also growing geriatric population and rise in the incidence rate of venous thromboembolism will boost the market growth. High treatment cost and side effects associated with VTE drugs hinder market growth. Increase patient awareness concerning VTE treatment may create lucrative opportunities in the near future.
On the basis of region, the venous thromboembolism therapeutics market is divided into North America, Europe, Asia-Pacific, and (RoW). North America region is the leading
region in the venous thromboembolism therapeutics market. Increase adoption for advance treatment and rising geriatric population are some of the factors responsible for driving growth in this region. Asia-Pacific region is an emerging market for venous thromboembolism therapeutics due to the developing healthcare infrastructure and rising government expenditure in the healthcare industry.
The report on global venous thromboembolism therapeutics market covers segments such as drug class and geographical. On the basis of drug class, the global venous thromboembolism therapeutics market is categorized into factor XA inhibitors, direct thrombin inhibitors, heparin, and vitamin K antagonists.
The report provides regional analysis covering geographies such as North America, Europe, Asia-Pacific, and Rest of the World. In this section, the key trends and market size for each geography are provided over the period of 2016-2024. The countries covered in the North America region include the U.S., Canada, and Mexico; while Asia-Pacific includes China, Japan, India, South Korea, Malaysia, and among others. Moreover, Germany, U.K., France, Spain, and Rest of Europe are included in the European region. The U.S. drives the growth in the North America region as it is the largest market in the region. The Asia-Pacific region offers a substantial potential for the market growth owing to rapid growth in markets such as India and China. The APAC region is projected to experience growth at a CAGR of x.x% over the period of 2018-2024.
The report provides profiles of the companies in the global venous thromboembolism therapeutics market such as Bayer HealthCare, Boehringer Ingelheim, BMS, Daiichi Sankyo, Sanofi, Johnson & Johnson, Aspen Pharma, BioInvent International, eXIthera Pharmaceuticals and Gamma Therapeutics.
The report provides deep insights on demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the global venous thromboembolism therapeutics market. Moreover, IGR-Growth Matrix analysis given in the report brings an insight on the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of venous thromboembolism therapeutics market. Moreover, the study highlights current market trends and provides forecast from 2018-2024. We also have highlighted future trends in the venous thromboembolism therapeutics market that will impact the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight on the market share of the leading players. This report will help manufacturers, suppliers, and distributors of the venous thromboembolism therapeutics market to understand the present and future trends in this market and formulate their strategies accordingly.